These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36251490)

  • 21. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
    Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu YH; He JS; Qiao W; Jiao YY; Hua Y; Zhang Y; Peng XL; Hong T
    Virol J; 2013 Jun; 10():183. PubMed ID: 23742026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucosal immunization with an adenoviral vector vaccine confers superior protection against RSV compared to natural immunity.
    Maier C; Fuchs J; Irrgang P; Wißing MH; Beyerlein J; Tenbusch M; Lapuente D
    Front Immunol; 2022; 13():920256. PubMed ID: 36003372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
    Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
    PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin.
    Lee YN; Hwang HS; Kim MC; Lee YT; Kim YJ; Lee FE; Kang SM
    Nanomedicine; 2016 Apr; 12(3):759-770. PubMed ID: 26656630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
    Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sublingual administration of a helper-dependent adenoviral vector expressing the codon-optimized soluble fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in mice.
    Fu YH; Jiao YY; He JS; Giang GY; Zhang W; Yan YF; Ma Y; Hua Y; Zhang Y; Peng XL; Shi CX; Hong T
    Antiviral Res; 2014 May; 105():72-9. PubMed ID: 24560779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study.
    Langley JM; MacDonald LD; Weir GM; MacKinnon-Cameron D; Ye L; McNeil S; Schepens B; Saelens X; Stanford MM; Halperin SA
    J Infect Dis; 2018 Jul; 218(3):378-387. PubMed ID: 29617814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.
    Taleb SA; Al Thani AA; Al Ansari K; Yassine HM
    Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1817-1827. PubMed ID: 29876771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models.
    Saeland E; van der Fits L; Bolder R; Heemskerk-van der Meer M; Drijver J; van Polanen Y; Vaneman C; Tettero L; Serroyen J; Schuitemaker H; Callendret B; Langedijk JPM; Zahn RC
    Vaccine; 2022 Feb; 40(6):934-944. PubMed ID: 34973849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Profile of respiratory syncytial virus prefusogenic fusion protein nanoparticle vaccine.
    Blunck BN; Rezende W; Piedra PA
    Expert Rev Vaccines; 2021 Apr; 20(4):351-364. PubMed ID: 33733995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review.
    Shan J; Britton PN; King CL; Booy R
    Influenza Other Respir Viruses; 2021 Jul; 15(4):539-551. PubMed ID: 33764693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
    Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I
    J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus.
    Garg R; Theaker M; Martinez EC; van Drunen Littel-van den Hurk S
    Virology; 2016 Dec; 499():288-297. PubMed ID: 27721128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
    Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K
    PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Respiratory Syncytial Virus F Subunit Vaccine With AS02 Adjuvant Elicits Balanced, Robust Humoral and Cellular Immunity in BALB/c Mice.
    Zheng Y; Bian L; Zhao H; Liu Y; Lu J; Liu D; Zhang K; Song Y; Luo Y; Jiang C; Chen Y; Zhang Y; Kong W
    Front Immunol; 2020; 11():526965. PubMed ID: 33013922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.